Gensight Biologics (France) Executives
| SIGHT Stock | EUR 0.31 0.01 3.13% |
Gensight Biologics employs about 44 people. The company is managed by 8 executives with a total tenure of roughly 103 years, averaging almost 12.0 years of service per executive, having 5.5 employees per reported executive. Discussion of Gensight Biologics' management performance can provide insight into the enterprise performance.
| Bernard Gilly Chairman Chairman of the Board, CEO, Co-Founder |
Gensight |
Gensight Biologics Management Team Effectiveness
The company has return on total asset (ROA) of (0.3876) % which means that it has lost $0.3876 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.719) %, meaning that it generated substantial loss on money invested by shareholders. Gensight Biologics' management efficiency ratios could be used to measure how well Gensight Biologics manages its routine affairs as well as how well it operates its assets and liabilities.Gensight Biologics Workforce Comparison
Gensight Biologics SA is currently regarded as top stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 118,062. Gensight Biologics adds roughly 44.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Gensight Biologics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Gensight Biologics Price Series Summation is a cross summation of Gensight Biologics price series and its benchmark/peer.
Gensight Biologics Notable Stakeholders
A Gensight Biologics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Gensight Biologics often face trade-offs trying to please all of them. Gensight Biologics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Gensight Biologics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Bernard Gilly | Chairman of the Board, CEO, Co-Founder | Profile | |
| Serge Picaud | Scientific Board | Profile | |
| Scott Jeffers | Chief Officer | Profile | |
| Clothilde Caillet | Director Communication | Profile | |
| Pr Roska | Scientific Board | Profile | |
| Thomas Gidoin | Chief Officer | Profile | |
| JoseAlain MD | Vice Founder | Profile | |
| Prof Cepko | Scientific Board | Profile |
About Gensight Biologics Management Performance
The success or failure of an entity such as Gensight Biologics often depends on how effective the management is. Gensight Biologics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Gensight management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Gensight management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. GenSight Biologics S.A. was founded in 2012 and is headquartered in Paris, France. GENSIGHT BIOLOGICS is traded on Paris Stock Exchange in France.
Gensight Biologics Workforce Analysis
Traditionally, organizations such as Gensight Biologics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Gensight Biologics within its industry.Gensight Biologics Manpower Efficiency
Return on Gensight Biologics Manpower
| Revenue Per Employee | 119.9K | |
| Revenue Per Executive | 659.5K | |
| Net Loss Per Employee | 650.4K | |
| Net Loss Per Executive | 3.6M |
Additional Tools for Gensight Stock Analysis
When running Gensight Biologics' price analysis, check to measure Gensight Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gensight Biologics is operating at the current time. Most of Gensight Biologics' value examination focuses on studying past and present price action to predict the probability of Gensight Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gensight Biologics' price. Additionally, you may evaluate how the addition of Gensight Biologics to your portfolios can decrease your overall portfolio volatility.